Mark Westerman, Ph.D.
Mark Westerman founded Intrinsic LifeSciences (ILS) in 2006 along with Drs. Tomas Ganz and Elizabeta Nemeth, and served as President & CEO until his passing.
Dr. Westerman and his corporate and academic colleagues discovered and characterized bass hepcidin soon after its discovery in humans by Tomas Ganz (UCLA, David Geffen School of Medicine). He was instrumental in development of a novel serum hepcidin ELISA and was awarded two patents related to the company’s products.
Mark Westerman’s Selected Publications:
- • Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors.
- • Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project.
- • Hepcidin in trauma: linking injury, inflammation, and anemia.
- • Urinary hepcidin: an inverse biomarker of acute kidney injury after cardiopulmonary bypass?
- • Hepcidin–a potential novel biomarker for iron status in chronic kidney disease.
- • Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women.
- • Immunoassay for human serum hepcidin.
- • A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
- • Bass hepcidin synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections.
- • Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge.
For the full list of publications, click here http://www.ncbi.nlm.nih.gov/pubmed?term=hepcidin%20OR%20la%20jolla%20OR%20college%20station%20AND%20westerman%20m